Related Experiment Video
Updated: Sep 24, 2026

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease
Published on: February 9, 2016
[Cimetidine and tripotassium-dicitrato bismuthate (Duosol) in chronic duodenal ulcer]
Abstract:
In an open study, 40 patients with duodenal ulcer of several years' standing were treated for relapse with either TDB (De-Nol) or cimetidine. No difference in the relapse rate was observed during the subsequent 12 months. Analysis of the data in relation to smoking habits did, however, reveal an advantage (p less than 0.05) for non-smokers during the first 6 months.
Related Concept Videos
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...

